Last reviewed · How we verify
Lacidipine & Amlodipine
Lacidipine & Amlodipine is a Dihydropyridine calcium channel blocker Small molecule drug developed by Korea University Guro Hospital. It is currently FDA-approved for Hypertension, Angina pectoris.
Lacidipine and amlodipine are dihydropyridine calcium channel blockers that inhibit L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure.
Lacidipine and amlodipine are dihydropyridine calcium channel blockers that inhibit L-type calcium channels in vascular smooth muscle and cardiac tissue, causing vasodilation and reducing blood pressure. Used for Hypertension, Angina pectoris.
At a glance
| Generic name | Lacidipine & Amlodipine |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Dihydropyridine calcium channel blocker |
| Target | L-type voltage-gated calcium channel |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Both agents block the influx of calcium ions through voltage-gated L-type calcium channels in the cell membrane of vascular smooth muscle cells. This prevents smooth muscle contraction and causes peripheral vasodilation, reducing systemic vascular resistance and lowering blood pressure. Amlodipine has a longer half-life and slower onset than lacidipine, allowing for once-daily dosing.
Approved indications
- Hypertension
- Angina pectoris
Common side effects
- Peripheral edema
- Headache
- Flushing
- Dizziness
- Palpitations
Key clinical trials
- Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study
- The Efficacy And Safety Of Lacidipine And Amlodipine Once-Daily Treatment In Hypertensive Adult Patients (PHASE4)
- Efficacy and Safety of Lacidipine and Amlodipine on Blood Pressure in Korean ISH Patients Aged 60 to 80 Years (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lacidipine & Amlodipine CI brief — competitive landscape report
- Lacidipine & Amlodipine updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI
Frequently asked questions about Lacidipine & Amlodipine
What is Lacidipine & Amlodipine?
How does Lacidipine & Amlodipine work?
What is Lacidipine & Amlodipine used for?
Who makes Lacidipine & Amlodipine?
What drug class is Lacidipine & Amlodipine in?
What development phase is Lacidipine & Amlodipine in?
What are the side effects of Lacidipine & Amlodipine?
What does Lacidipine & Amlodipine target?
Related
- Drug class: All Dihydropyridine calcium channel blocker drugs
- Target: All drugs targeting L-type voltage-gated calcium channel
- Manufacturer: Korea University Guro Hospital — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Hypertension
- Indication: Drugs for Angina pectoris
- Compare: Lacidipine & Amlodipine vs similar drugs
- Pricing: Lacidipine & Amlodipine cost, discount & access